CN119709650A - 溶瘤病毒及其应用 - Google Patents

溶瘤病毒及其应用 Download PDF

Info

Publication number
CN119709650A
CN119709650A CN202411986086.XA CN202411986086A CN119709650A CN 119709650 A CN119709650 A CN 119709650A CN 202411986086 A CN202411986086 A CN 202411986086A CN 119709650 A CN119709650 A CN 119709650A
Authority
CN
China
Prior art keywords
virus
cells
oncolytic virus
oncolytic
present application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411986086.XA
Other languages
English (en)
Chinese (zh)
Inventor
周国庆
张凡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Rongrui Pharmaceutical Technology Co ltd
Original Assignee
Shanghai Rongrui Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Rongrui Pharmaceutical Technology Co ltd filed Critical Shanghai Rongrui Pharmaceutical Technology Co ltd
Priority to CN202411986086.XA priority Critical patent/CN119709650A/zh
Publication of CN119709650A publication Critical patent/CN119709650A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20251—Methods of production or purification of viral material
    • C12N2760/20252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202411986086.XA 2022-01-26 2022-01-26 溶瘤病毒及其应用 Pending CN119709650A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411986086.XA CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210094869.1A CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986086.XA CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202210094869.1A Division CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Publications (1)

Publication Number Publication Date
CN119709650A true CN119709650A (zh) 2025-03-28

Family

ID=81673943

Family Applications (6)

Application Number Title Priority Date Filing Date
CN202411986086.XA Pending CN119709650A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986368.XA Pending CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A Pending CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202210094869.1A Active CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986002.2A Pending CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986426.9A Pending CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Family Applications After (5)

Application Number Title Priority Date Filing Date
CN202411986368.XA Pending CN119709652A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986145.3A Pending CN119709651A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202210094869.1A Active CN114540316B (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986002.2A Pending CN119709649A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用
CN202411986426.9A Pending CN119736261A (zh) 2022-01-26 2022-01-26 溶瘤病毒及其应用

Country Status (8)

Country Link
US (1) US20240424040A1 (enExample)
EP (1) EP4471132A4 (enExample)
JP (1) JP2025503188A (enExample)
KR (1) KR20240137069A (enExample)
CN (6) CN119709650A (enExample)
AU (1) AU2023210771A1 (enExample)
CA (1) CA3243385A1 (enExample)
WO (1) WO2023143023A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN116350759A (zh) * 2023-03-30 2023-06-30 上海荣瑞医药科技有限公司 溶瘤病毒疫苗和免疫细胞联合治疗肿瘤的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1769433B (zh) * 2004-11-04 2011-03-16 张庆勇 重组水疱性口炎病毒及其应用
RU2010124788A (ru) * 2007-12-21 2012-01-27 Ваейт ЭлЭлСи (US) Генетически модифицированный ослабленный вирус везикулярного стоматита, композиции и способы их применения
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
CN105087645A (zh) * 2015-08-04 2015-11-25 上海交通大学 M蛋白三氨基酸位点突变的猪用vsv病毒载体构建和应用
EP3246410A1 (en) * 2016-05-19 2017-11-22 Klinikum rechts der Isar der Technischen Universität München Vsv/ndv hybrid viruses for oncolytic therapy of cancer
CN110305198B (zh) * 2018-03-27 2021-01-29 睿丰康生物医药科技(浙江)有限公司 一种溶瘤棒状病毒减毒株及其在肿瘤治疗中的应用
CN110819657B (zh) * 2018-08-10 2021-11-19 睿丰康生物医药科技(浙江)有限公司 一种减毒棒状病毒的制备方法及应用
TWI894135B (zh) * 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
CN111467489B (zh) * 2020-05-12 2022-06-03 上海荣瑞医药科技有限公司 一种治疗肿瘤的药物
CN111286493B (zh) * 2020-05-12 2020-10-27 上海荣瑞医药科技有限公司 一种溶瘤病毒疫苗及其与免疫细胞联合治疗肿瘤的药物
CN113832114A (zh) * 2020-06-23 2021-12-24 南京大学 一种新型溶瘤腺病毒EM/VSV-G Ad5-P及其在制备抗肿瘤药物中的应用
CN119709650A (zh) * 2022-01-26 2025-03-28 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117402837A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 一种重组溶瘤病毒及其应用
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用

Also Published As

Publication number Publication date
JP2025503188A (ja) 2025-01-30
US20240424040A1 (en) 2024-12-26
CN119709652A (zh) 2025-03-28
CN114540316B (zh) 2025-01-03
CN119709651A (zh) 2025-03-28
AU2023210771A1 (en) 2024-08-15
CN119736261A (zh) 2025-04-01
CA3243385A1 (en) 2025-06-17
KR20240137069A (ko) 2024-09-19
CN119709649A (zh) 2025-03-28
EP4471132A4 (en) 2026-02-25
EP4471132A1 (en) 2024-12-04
WO2023143023A1 (zh) 2023-08-03
CN114540316A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7468958B2 (ja) 腫瘍溶解性ウイルスワクチン及びそれと免疫細胞の併用による腫瘍治療薬物
CN114540316B (zh) 溶瘤病毒及其应用
US20230190838A1 (en) Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors
JP2025503188A5 (enExample)
EP4545634A1 (en) Recombinant oncolytic virus and use thereof
AU2018303064B2 (en) Virus for treating tumors
AU2019254948B2 (en) Coxsackie virus B for treating tumors
CN115612674B (zh) 一种溶瘤病毒及其用途
HK40105653A (en) Oncolytic virus and use thereof
JP2023526905A (ja) マイクロｒｎａで調節及び制御可能な単離された組換え腫瘍溶解性ポックスウイルス及びその使用
CA3070628C (en) Enterovirus d68 (ev-d68) for treatment of tumor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination